|
1
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Folkman J: Angiogenesis in cancer,
vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Folkman J: Tumor angiogenesis: A possible
control point in tumor growth. Ann Intern Med. 82:96–100. 1975.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Carmeliet P: Mechanisms of angiogenesis
and arteriogenesis. Nat Med. 6:389–395. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ferrara N and Kerbel RS: Angiogenesis as a
therapeutic target. Nature. 438:967–974. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Salvucci O and Tosato G: Essential roles
of EphB receptors and EphrinB ligands in endothelial cell function
and angiogenesis. Adv Cancer Res. 114:21–57. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pitulescu ME and Adams RH: Eph/ephrin
molecules - a hub for signaling and endocytosis. Genes Dev.
24:2480–2492. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pasquale EB: Eph-ephrin bidirectional
signaling in physiology and disease. Cell. 133:38–52. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chrencik JE, Brooun A, Recht MI, Kraus ML,
Koolpe M, Kolatkar AR, Bruce RH, Martiny-Baron G, Widmer H,
Pasquale EB, et al: Structure and thermodynamic characterization of
the EphB4/Ephrin-B2 antagonist peptide complex reveals the
determinants for receptor specificity. Structure. 14:321–330. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sawamiphak S, Seidel S, Essmann CL,
Wilkinson GA, Pitulescu ME, Acker T and Acker-Palmer A: Ephrin-B2
regulates VEGFR2 function in developmental and tumour angiogenesis.
Nature. 465:487–491. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Y, Nakayama M, Pitulescu ME, Schmidt
TS, Bochenek ML, Sakakibara A, Adams S, Davy A, Deutsch U, Lüthi U,
et al: Ephrin-B2 controls VEGF-induced angiogenesis and
lymphangiogenesis. Nature. 465:483–486. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gomez MC, Bravo GB, Caceres CG, Gongora A
and Baldi A: The eph/ephrin system, an example of versatility and
functional diversity in molecular biology of cancer and
angiogenesis. Acta Bioquim Clin Latinoam. 4:675–679. 2011.
|
|
14
|
Steinle JJ, Meininger CJ, Chowdhury U, Wu
G and Granger HJ: Role of ephrin B2 in human retinal endothelial
cell proliferation and migration. Cell Signal. 15:1011–1017. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maekawa H, Oike Y, Kanda S, Ito Y, Yamada
Y, Kurihara H, Nagai R and Suda T: Ephrin-B2 induces migration of
endothelial cells through the phosphatidylinositol-3 kinase pathway
and promotes angiogenesis in adult vasculature. Arterioscler Thromb
Vasc Biol. 23:2008–2014. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gao H, Su P, Shi Y, Shen X, Zhang Y, Dong
J and Zhang J: Discovery of novel VEGFR-2 inhibitors. Part II:
Biphenyl urea incorporated with salicylaldoxime. Eur J Med Chem.
90:232–240. 2015. View Article : Google Scholar
|
|
17
|
Dai B, Zhang Y, Zhan Y, Zhang D, Wang N
and He L: A novel tissue model for angiogenesis: Evaluation of
inhibitors or promoters in tissue level. Sci Rep. 4:36932014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Grootjans JJ, Reekmans G, Ceulemans H and
David G: Syntenin-syndecan binding requires syndecan-synteny and
the co-operation of both PDZ domains of syntenin. J Biol Chem.
275:19933–19941. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dev KK: PDZ domain protein-protein
interactions: A case study with PICK1. Curr Top Med Chem. 7:3–20.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Thorat MA and Cuzick J: Role of aspirin in
cancer prevention. Curr Oncol Rep. 15:533–540. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lou L, Ye W, Chen Y, Wu S, Jin L, He J,
Tao X, Zhu J, Chen X, Deng A, et al: Ardipusilloside inhibits
survival, invasion and metastasis of human hepatocellular carcinoma
cells. Phytomedicine. 19:603–608. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nielsen JS and McNagny KM: Novel functions
of the CD34 family. J Cell Sci. 121:3683–3692. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chew A, Salama P, Robbshaw A, Klopcic B,
Zeps N, Platell C and Lawrance IC: SPARC, FOXP3, CD8 and CD45
correlation with disease recurrence and long-term disease-free
survival in colorectal cancer. PLoS One. 6:e220472011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cantley LC: The phosphoinositide 3-kinase
pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Simpson L and Parsons R: PTEN: Life as a
tumor suppressor. Exp Cell Res. 264:29–41. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhong H, De Marzo AM, Laughner E, Lim M,
Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons
JW: Overexpression of hypoxia-inducible factor 1alpha in common
human cancers and their metastases. Cancer Res. 59:5830–5835.
1999.PubMed/NCBI
|
|
27
|
Bos R, van der Groep P, Greijer AE,
Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ and van
der Wall E: Levels of hypoxia-inducible factor-1alpha independently
predict prognosis in patients with lymph node negative breast
carcinoma. Cancer. 97:1573–1581. 2003. View Article : Google Scholar : PubMed/NCBI
|
